Asprosin in Breast Cancer

NCT06592560 | Not Yet Recruiting

• 1 other identifier: Asprosin
• Study Type: observational
• Target: 84
• Locations: 0 countries
• Sites: N/A

Brief Summary

To evaluate the clinical utility of Asprosin measurement in breast cancer patients in comparison with healthy controls and patients with benign breast lesions. To compare between Asprosin and the routine markers (CEA, CA15-3) as biomarkers for breast cancer diagnosis

Conditions

Breast Cancer

Outcome Measures

Primary Outcomes (1)

• Diagnostic value of Asprosin as a biomarker in breast cancer

  Evaluation of the clinical utility of measurement of asprosin as a non invasive biomarker in the diagnosis of breast cancer

  Baseline

Secondary Outcomes (1)

• Diagnostic value of Asprosin as a biomarker in breast cancer

  Baseline

Study Arms (3)

Healthy people

Device: ELISA

Patients with benign breast lesions

Device: ELISA

Patients with breast cancer

Device: ELISA

Interventions

ELISA DEVICE

Specific test: Assay of asprosin marker will be measured by enzyme-linked immunosorbent assay ( ELISA).

Healthy people; Patients with benign breast lesions; Patients with breast cancer

Eligibility Criteria

• Age: 18 Years - 60 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)
• Sampling Method: Non-Probability Sample

Study Population

Group 1: healthy controls from healthy volunteers. Group 2: patients with benign breast lesions. Group 3: breast cancer patients

You may qualify if:

• Females aged (40 ± 20 years) who did not receive any chemotherapy or surgical treatment and they will be divided as follow:
• Group 1: healthy controls from healthy volunteers. Group 2: patients with benign breast lesions. Group 3: breast cancer patients.

You may not qualify if:

• Female patients with any other type of malignant or benign tumors. 2- Past history of chemotherapy or surgical treatment of cancer.

Sponsors & Collaborators

• Marina Hanna Thabet Ghobrial: lead

MeSH Terms

Conditions

Breast Neoplasms

Interventions

Enzyme-Linked Immunosorbent Assay

Condition Hierarchy (Ancestors)

Neoplasms by Site; Neoplasms; Breast Diseases; Skin Diseases; Skin and Connective Tissue Diseases

Intervention Hierarchy (Ancestors)

Immunoenzyme Techniques; Immunoassay; Immunologic Techniques; Investigative Techniques; Immunosorbent Techniques; Immunohistochemistry; Molecular Probe Techniques

Central Study Contacts

Marina Hanna Thabet

CONTACT

01007970949; hannamarina626@gmail.com

Eman Mohamed Abdelrahman

CONTACT

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Assistant Lecturer

Study Record Dates

• First Submitted: September 10, 2024
• First Posted: September 19, 2024
• Study Start: October 1, 2024
• Primary Completion: September 1, 2025
• Study Completion: October 1, 2025
• Last Updated: September 19, 2024

Record last verified: 2024-09

Data Sharing

• IPD Sharing: Will not share